Like the original PST® test, PerioPredict™ measures variations in the genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at an increased risk for more severe periodontal (gum) disease. The new and improved sample collection device now utilizes a simple, easy-to-use cheek swab. The new test also utilizes an expansion of previous genetic markers that now cover all major ethnic groups including Hispanic, African-American, and Asian, in addition to Caucasian. PerioPredict™ is quick, easy, and painless. It is performed by dentists or dental hygienists in about a minute during a routine exam or cleaning. The sample is then sent to Interleukin Genetics, Inc., a CLIA-certified genetics laboratory, for analysis. Test results are returned to the dentist in about two weeks. A positive PerioPredict™ test result means that your patient does have the genetic variation that increases risk for severe periodontal disease. A negative PerioPredict™ test result means that your patient does not have the genetic variation that increases risk for severe periodontal disease. For more information on the test results and their interpretation, look at the Inform and Plan section of the website.(2)
Interleukin Genetics, Inc. announced recently the introduction of PerioPredict™, the company’s new, next-generation version of the PST® genetic risk test for periodontal disease. PerioPredict™ will be broadly available beginning January 2014.(1)
